Niamh Corduff1,2,3,4,5,6,7,8,9,10,11,12,13, Jeng Feng Chen1,2,3,4,5,6,7,8,9,10,11,12,13, Ya Hui Chen1,2,3,4,5,6,7,8,9,10,11,12,13, Ho Sung Choi1,2,3,4,5,6,7,8,9,10,11,12,13, Kate Goldie1,2,3,4,5,6,7,8,9,10,11,12,13, Yui Lam1,2,3,4,5,6,7,8,9,10,11,12,13, Nyoman Indra Lesthari1,2,3,4,5,6,7,8,9,10,11,12,13, Ting Song Lim1,2,3,4,5,6,7,8,9,10,11,12,13, Suzanna Luo1,2,3,4,5,6,7,8,9,10,11,12,13, Arnelle Quiambao1,2,3,4,5,6,7,8,9,10,11,12,13, Tuck Wah Siew1,2,3,4,5,6,7,8,9,10,11,12,13, Fang Wen Tseng1,2,3,4,5,6,7,8,9,10,11,12,13, Yates Y Y Chao1,2,3,4,5,6,7,8,9,10,11,12,13. 1. Dr. Corduff is with the Cosmetic Refinement Clinic in Geelong, Australia. 2. Dr. J. F. Chen is with Tri-Service General Hospital in Taipei, Taiwan. 3. Dr. Y. H. Chen is with YaSkin Dermatology Clinic in Kaohsiung, Taiwan. 4. Dr. Choi is with PIENA Aesthetic Medical Clinic in Gangnam, Seoul, South Korea. 5. Ms. Goldie is with European Medical Aesthetics in London, England. 6. Dr. Lam is with the Skin Care Clinic in Tsim Sha Tsui, Hong Kong. 7. Lesthari is with Sano Clinic in Denpasar, Bali, Indonesia. 8. Dr. Lim is with Clique Clinic in Petaling Jaya, Selangor, Malaysia. 9. Ms. Luo is with Medical Aesthetics 360 in Hurstville, New South Wales, Australia. 10. Dr. Quiambao is with YouPlus Intelligent Aesthetic Clinic in Taguig City, the Philippines. 11. Dr. Siew is with Radium Medical Aesthetics in Singapore. 12. Dr. Tsend is with Milano Aesthetic Clinic in Taoyuan, Taiwan. 13. Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan.
Abstract
BACKGROUND: Several usage guidelines for calcium hydroxylapatite (CaHA), a dermal filler material, exist for non-Asian patients, making it necessary to determine whether their findings and consensuses are applicable to Asian patients who have distinct anatomies, cultural preferences, and aesthetic requests. OBJECTIVE: We sought to develop a Pan-Asian consensus on CaHA use in skin biostimulation, contouring, and combination treatments for face and body indications. METHODS: A survey on CaHA usage for contouring and biostimulation indications in Asian patients was conducted, followed by discussions to establish consensus statements and topics for examination. RESULTS: Several aspects of facial shaping and contouring or skin biostimulation with CaHA were agreed on, including that dilution is not a key consideration, that microfocused ultrasound with visualisation precedes CaHA in same day or session treatments, and that cannulas should be used. Among the many agreements on interventions in specific facial and body areas, there were also disagreements due to the diverse Asian patient presentations, requests, and access to tools or products; for example, CaHA should be placed in the interfascial layer for temple contouring, CaHA should not be injected directly into the infraorbital area for safety, and diluted CaHA should be injected subdermally for nonfacial or whole-face biostimulation and contouring. CONCLUSION: Our disagreements highlight the diversity of Asian facial morphotypes and desired aesthetic outcomes and underscore the need for customized aesthetic strategies to accommodate the heterogeneity of Asian anatomies, cultural preferences, and aesthetic ideals. Establishing consensus statements on critical aspects of Asian patient considerations, efficacy and safety, is crucial. This document provides strategic guidance on the use of classic, diluted CaHA for biostimulation or undiluted Radiesse®(+) (Merz Pharma GmbH & Co. KGaA, Frankfurt, Germany) for lifting and contouring to ensure consistent CaHA delivery for successful patient outcomes.
BACKGROUND: Several usage guidelines for calcium hydroxylapatite (CaHA), a dermal filler material, exist for non-Asian patients, making it necessary to determine whether their findings and consensuses are applicable to Asian patients who have distinct anatomies, cultural preferences, and aesthetic requests. OBJECTIVE: We sought to develop a Pan-Asian consensus on CaHA use in skin biostimulation, contouring, and combination treatments for face and body indications. METHODS: A survey on CaHA usage for contouring and biostimulation indications in Asian patients was conducted, followed by discussions to establish consensus statements and topics for examination. RESULTS: Several aspects of facial shaping and contouring or skin biostimulation with CaHA were agreed on, including that dilution is not a key consideration, that microfocused ultrasound with visualisation precedes CaHA in same day or session treatments, and that cannulas should be used. Among the many agreements on interventions in specific facial and body areas, there were also disagreements due to the diverse Asian patient presentations, requests, and access to tools or products; for example, CaHA should be placed in the interfascial layer for temple contouring, CaHA should not be injected directly into the infraorbital area for safety, and diluted CaHA should be injected subdermally for nonfacial or whole-face biostimulation and contouring. CONCLUSION: Our disagreements highlight the diversity of Asian facial morphotypes and desired aesthetic outcomes and underscore the need for customized aesthetic strategies to accommodate the heterogeneity of Asian anatomies, cultural preferences, and aesthetic ideals. Establishing consensus statements on critical aspects of Asian patient considerations, efficacy and safety, is crucial. This document provides strategic guidance on the use of classic, diluted CaHA for biostimulation or undiluted Radiesse®(+) (Merz Pharma GmbH & Co. KGaA, Frankfurt, Germany) for lifting and contouring to ensure consistent CaHA delivery for successful patient outcomes.